Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
February 22 2017 - 08:05AM
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine
Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced
that the company will attend and participate at two upcoming life
sciences industry conferences. From February 27 through March
2, 2017, the company will host a corporate booth in the exhibit
hall at KNect365 Life Sciences’ BioProcess International West
conference, in addition to co-sponsoring the conference’s exhibit
hall opening night reception. On March 14, 2017, David Briggs,
Ph.D., a scientist in Avid’s process sciences department, will
discuss the expanding role of pre-packed columns in
biopharmaceutical manufacturing as part of a case study presented
during the Driving Bioprocessing Efficiency seminar.
Details of these activities are as follows:
KNect365 Life Sciences' BioProcess International West: February
27 - March 2, 2017, San Francisco, CA
Besides serving as a co-sponsor of the
conference’s exhibit hall opening night reception, Avid will host
corporate booth #816 showcasing the company’s comprehensive range
of process development and high quality cGMP clinical and
commercial manufacturing services for the biotechnology and
biopharmaceutical industries. These include a variety of
innovative processes for generating a broad range of
biopharmaceutical product types such as monoclonal antibodies,
highly-glycosylated recombinant proteins and enzymes, among
others. These capabilities also extend to the manufacture of
biosimilar products as well as antibody drug conjugate
intermediates and are designed to support the overall ongoing
growth of the company’s contract manufacturing business.
Company representatives will provide a virtual
tour of its 40,000 square foot state-of-the-art commercial
biomanufacturing facility (Myford facility) for those
interested. The Myford facility is designed to utilize the
most cutting-edge, single-use equipment to accommodate a fully
disposable biomanufacturing process for late Phase III clinical and
commercial production of biologics. The facility is capable
of operating in campaign mode whereby multiple bioreactors are
simultaneously in operation, which increases the facility’s
manufacturing capacity and efficiency. The Myford facility,
which was commissioned in 2016, was built to augment Avid’s
Franklin facility, which has been in operation since 1993 and
producing cGMP commercial products since 2005.
Driving Bioprocessing Efficiency Seminar: March
14, 2017, Carlsbad, CA
Dr. Briggs will present a case study profiling
the use of proprietary pre-packed columns in a cGMP environment and
the impact of this technology on reducing set-up and process time,
as well as capital and validation expense. This case study
will include an overview of Avid’s Myford facility and provide data
demonstrating the positive impact of pre-packed columns in a
multi-product manufacturing setting. The content of this
case study further showcases Avid’s utilization of the industry’s
most advanced products and technologies in its manufacturing
facilities.
For additional details on these events, please visit:
https://lifesciences.knect365.com/bpi-west/ and
www.repligen.com/sandiego2017.
About Avid BioservicesAvid Bioservices provides
a comprehensive range of process development, high quality cGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 15 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, Avid's services
include cGMP clinical and commercial product manufacturing,
purification, bulk packaging, stability testing and regulatory
strategy, submission and support. The company also provides a
variety of process development activities, including cell line
development and optimization, cell culture and feed optimization,
analytical methods development and product characterization. For
more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering
high quality pharmaceutical products through its contract
development and manufacturing organization (CDMO) services and
through advancing and licensing its investigational immunotherapy
and related products. Peregrine's in-house CDMO services,
including cGMP manufacturing and development capabilities, are
provided through its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. The
company is also working to evaluate its lead immunotherapy
candidate, bavituximab, in combination with immune stimulating
therapies for the treatment of various cancers, and developing its
proprietary exosome technology for the detection and monitoring of
cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2023 to Mar 2024